Epinephrine in Neonatal Resuscitation: IV vs Endotracheal Dose & Administration Guide

Epinephrine in Neonatal Resuscitation: A Critical Drug Review

Epinephrine (adrenaline) remains the only vasoactive drug recommended during active neonatal resuscitation by the American Academy of Pediatrics (AAP), International Liaison Committee on Resuscitation (ILCOR), and the National Neonatology Forum (NNF) of India. Understanding its pharmacology, correct dosing, optimal route of administration, and potential complications is essential for every NICU physician, neonatologist, and resuscitation team member. Incorrect dosing or route selection can mean the difference between a successful resuscitation and a devastating outcome.

Pharmacology of Epinephrine in the Neonate

Epinephrine is an endogenous catecholamine that acts on both alpha and beta adrenergic receptors. In the context of neonatal resuscitation, its primary therapeutic effects include:

• Alpha-1 receptor stimulation: Causes peripheral vasoconstriction, increasing systemic vascular resistance and raising aortic diastolic pressure, which is the primary determinant of coronary perfusion pressure
• Beta-1 receptor stimulation: Increases heart rate (chronotropy), contractile force (inotropy), and conduction velocity (dromotropy)
• Beta-2 receptor stimulation: Causes bronchodilation and may improve pulmonary blood flow at low doses

In a severely asphyxiated neonate with profound bradycardia, the most important mechanism is increasing coronary perfusion pressure through alpha-mediated vasoconstriction. Without adequate coronary perfusion, the myocardium cannot recover contractile function regardless of other interventions.

IV Epinephrine via Umbilical Venous Catheter: The Preferred Route

The umbilical venous catheter (UVC) is the gold standard vascular access for epinephrine delivery during neonatal resuscitation. NRP 8th edition (2021) and NNF India guidelines both emphasize that IV epinephrine should be the first-line route whenever possible.

UVC Insertion Technique for Emergency Drug Access

1. Cut the umbilical cord cleanly at 1-2 cm from the abdominal wall using a sterile blade
2. Identify the single large, thin-walled umbilical vein (as opposed to the two thick-walled arteries)
3. Insert a pre-flushed 3.5F catheter (for neonates below 2 kg) or 5F catheter (for neonates above 2 kg) into the vein
4. Advance 2-4 cm until free-flowing blood return is obtained on gentle aspiration
5. Do not advance further to avoid hepatic or cardiac positioning in an emergency
6. Secure with a purse-string suture or tape bridge

IV Epinephrine Dosing Protocol

Parameter	Specification
Concentration	1:10,000 (0.1 mg/mL)
Dose range	0.01-0.03 mg/kg
Volume range	0.1-0.3 mL/kg
Administration	Rapid IV push via UVC
Flush	0.5-1 mL normal saline immediately after
Repeat interval	Every 3-5 minutes
Maximum recommended dose	0.03 mg/kg per dose

Clinical Pearl: Always start at the lower dose (0.01 mg/kg) for the first IV dose. If there is no response after 3-5 minutes, escalate to the higher end (0.03 mg/kg) for subsequent doses. Doses above 0.03 mg/kg IV are not recommended due to increased risk of adverse effects without proven additional benefit in neonates.

Endotracheal Epinephrine: When IV Access Is Delayed

Endotracheal (ET) epinephrine should only be considered when IV access via UVC cannot be established rapidly. The NRP guidelines note that while ET epinephrine may be given while UVC access is being obtained, it should not replace the IV route as the definitive treatment.

Endotracheal Dosing Protocol

Parameter	Specification
Concentration	1:10,000 (0.1 mg/mL)
Dose range	0.05-0.1 mg/kg
Volume range	0.5-1.0 mL/kg
Administration	Direct instillation into ETT
Follow-up	Several positive pressure breaths

Why the ET Dose Is Higher

The endotracheal dose is 3-10 times the IV dose because of significantly reduced and unpredictable drug absorption through the pulmonary epithelium. During cardiac arrest, pulmonary blood flow is markedly reduced, further limiting drug uptake from the alveoli. Studies in animal models and limited human data demonstrate that plasma epinephrine levels achieved via ET administration are only 10-30% of those achieved with equivalent IV doses. This pharmacokinetic disadvantage makes the ET route a temporizing measure at best.

Weight-Based Epinephrine Quick Reference

Weight (kg)	IV Dose (mL of 1:10,000)	ET Dose (mL of 1:10,000)
0.5	0.05-0.15	0.25-0.5
1.0	0.1-0.3	0.5-1.0
1.5	0.15-0.45	0.75-1.5
2.0	0.2-0.6	1.0-2.0
2.5	0.25-0.75	1.25-2.5
3.0	0.3-0.9	1.5-3.0
3.5	0.35-1.05	1.75-3.5
4.0	0.4-1.2	2.0-4.0

Alternative Vascular Access: Intraosseous Route

When UVC access fails and time is critical, the intraosseous (IO) route is an acceptable alternative. The proximal tibia is the standard insertion site in neonates. IO access provides rapid drug delivery equivalent to IV administration. However, IO use in very low birth weight preterm neonates carries higher risk of tibial fracture and osteomyelitis. In Indian NICUs, IO needles should be available in all resuscitation carts as a backup access option per NNF recommendations.

Drug Safety and Adverse Effects

Epinephrine, while lifesaving, carries significant risks especially in the neonatal population:

• Hypertension: Excessive doses can cause severe systemic hypertension, increasing the risk of intraventricular hemorrhage (IVH) in preterm neonates
• Tachyarrhythmias: Supraventricular and ventricular tachycardia can occur, particularly with doses exceeding 0.03 mg/kg
• Myocardial ischemia: Increased myocardial oxygen demand may worsen ischemic injury in a severely asphyxiated heart
• Tissue necrosis: Extravasation from a peripheral IV causes severe local vasoconstriction and tissue necrosis; phentolamine infiltration may be needed for treatment
• Hyperglycemia: Epinephrine stimulates glycogenolysis, potentially causing rebound hyperglycemia followed by hypoglycemia

Contraindications and Precautions

There are no absolute contraindications to epinephrine in a neonate with a heart rate below 60 bpm who has not responded to ventilation and compressions. However, the following precautions should be observed:

• Always verify 1:10,000 concentration; never use undiluted 1:1,000 (1 mg/mL)
• Use a separate syringe clearly labeled with drug name, concentration, and dose
• Flush the UVC line with normal saline after each dose to ensure complete delivery
• Monitor heart rate continuously; stop escalation once HR exceeds 60 bpm

Evidence Review: ILCOR 2020 and NRP 8th Edition Updates

The ILCOR 2020 Consensus on Science and Treatment Recommendations reinforced the following key points regarding epinephrine use in neonatal resuscitation:

• IV epinephrine via UVC remains the preferred route with the strongest evidence base
• ET epinephrine may be considered while IV access is being established but should not delay IV administration
• There is insufficient evidence to recommend higher-dose IV epinephrine (above 0.03 mg/kg) in neonates
• Early UVC placement should be prioritized; simulation training should include rapid UVC insertion skills

The NRP 8th edition (2021) further emphasizes the importance of team-based resuscitation with predefined roles, where one team member is specifically assigned to drug preparation and administration. This approach, increasingly adopted in Indian Level III NICUs, reduces medication errors and improves time-to-drug-delivery. HEAMAC supports NICU teams with comprehensive emergency drug protocol resources to facilitate adherence to these updated guidelines.

Monitoring After Epinephrine Administration

Post-resuscitation monitoring after epinephrine administration should include:

• Continuous heart rate monitoring via pulse oximetry and cardiac monitor
• Invasive blood pressure monitoring via umbilical arterial catheter when available
• Blood glucose monitoring every 30-60 minutes for the first 6 hours
• Arterial blood gas analysis to assess acid-base status
• Echocardiography within 24 hours to assess cardiac function
• Cranial ultrasound within 48 hours in preterm neonates to screen for IVH

Conclusion: Optimizing Epinephrine Use in Indian NICUs

Epinephrine remains the cornerstone pharmacological intervention in neonatal resuscitation. Mastery of its correct dosing, preferred route of administration, and safety profile is non-negotiable for every NICU practitioner. Indian NICUs at both Level II and Level III should maintain pre-drawn epinephrine syringes, conduct regular resuscitation drills, and ensure that dosing reference charts are prominently displayed at every delivery station and resuscitation bay. The goal is zero preventable deaths from drug errors during neonatal resuscitation.